SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311: 899909.
  • 2
    Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small cell lung cancer. Br J Cancer. 2000; 83: 447453.
  • 3
    Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92: 10741080.
  • 4
    Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000; 27: 145157.
  • 5
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effect of vinorelbine on quality of life an survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999; 91: 6672.
  • 6
    Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol. 1992; 10: 1620.
  • 7
    Han JY, Lee DH, Kim HY, et al. A phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clin Cancer Res. 2003; 9: 59095914.
  • 8
    Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol. 1997; 8: 837855.
  • 9
    Douillard J, Ibrahim N, Riviere A, et al. Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 1995; 14: 365.
  • 10
    Baker L, Khan R, Lynch T, et al. Phase II study of irinotecan (CPT-11) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 1997; 16: 461a.
  • 11
    Masuda N, Fukuoka M, Takada M, et al. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol. 1992; 10: 17751780.
  • 12
    Mori K, Machida S, Yoshida T, et al. A phase II study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 1999; 43: 467470.
  • 13
    DeVore RF, Johnson DH, Crawford J, et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer. J Clin Oncol. 1999; 17: 27102720.
  • 14
    Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34: 12741281.
  • 15
    Van Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000; 18: 13371345.
  • 16
    Bajetta E, Di Bartolomeo M, Mariani L, et al. Italian Trials in Medical Oncology (I.T.M.O.) Group. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer. 2004; 100: 279287.
  • 17
    Tewes M, Schleucher N, Achterrath W, et al. Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. Ann Oncol. 2003; 14: 14421448.
  • 18
    Jordan K, Grothey A, Kellner A, et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer (ACRC): results of an interim analysis. Proc Am Soc Clin Oncol. 2002; 21: 103b.
  • 19
    World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Pub. No. 48. Geneva: World Health Organization, 1979.
  • 20
    Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 21
    Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 22
    Partridge AH, Avoin J, Wang SP, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002; 94: 652661.
  • 23
    Giatromanolaki A, Koukourakis MI, Comley M, et al. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol. 1997; 181: 196199.
  • 24
    Han JY, Hong EK, Lee SY, Yoon SM, Lee DH, Lee JS. Thymidine phosphorylase expression in tumour cells and tumour response to capecitabine plus docetaxel chemotherapy in non-small cell lung cancer. J Clin Pathol. 2005; 58: 650654.
  • 25
    O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20: 28122823.
  • 26
    Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4: 10131019.
  • 27
    Han JY, Lee DH, Kim HY, et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced non-small cell lung cancer (NSCLC). Cancer. 2003; 98: 19181924.
  • 28
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002; 346: 9298.
  • 29
    Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer. 2002; 38(Suppl 4): 512.